Engineered probiotic Lactobacillus plantarum WCSF I for monitoring and treatment of Staphylococcus aureus infection

Microbiol Spectr. 2023 Dec 12;11(6):e0182923. doi: 10.1128/spectrum.01829-23. Epub 2023 Nov 1.

Abstract

Bacterial infection and the emergence of drug-resistant strains are major problems in clinical treatment. Staphylococcus aureus, which typically infects the skin and blood of animals, is also a potential intestinal pathogen that needs to be addressed by the emergence of a new treatment approach. Probiotic therapy is the most likely alternative to antibiotic therapy to solve the problem of bacterial drug resistance in clinical practice. In this study, the engineered Lactobacillus plantarum can not only sense the signal AIP to detect S. aureus but also kill S. aureus by secreting the lysostaphin enzyme. Our strategy employed an Agr quorum-sensing genetic circuit to simultaneously detect and treat pathogenic bacteria, which provided a theoretical possibility for solving practical clinical bacterial infection cases in the future.

Keywords: Agr quorum-sensing system; Lactobacillus plantarum WCSF I; Staphylococcus aureus; biosensors; lysostaphin enzyme; self-inducing peptide.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics
  • Lactobacillus plantarum* / genetics
  • Probiotics* / therapeutic use
  • Quorum Sensing
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology
  • Staphylococcus aureus / genetics

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins